CAS No.:51481-61-9

TOXICITY DATA with REFERENCE：

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
child	TDLo	intravenous	100mg/kg (100mg/kg)	CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP	Annals of Internal Medicine. Vol. 97, Pg. 283, 1982.
dog	LD50	intravenous	206mg/kg (206mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE GASTROINTESTINAL: OTHER CHANGES	Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 2806, 1980.
dog	LD50	oral	2600mg/kg (2600mg/kg)		Pharmacological and Biochemical Properties of Drug Substances. Vol. 1, Pg. 329, 1977.
hamster	LD50	intraperitoneal	880mg/kg (880mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Gastroenterology. Vol. 74, Pg. 339, 1978.
hamster	LD50	oral	4gm/kg (4000mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Gastroenterology. Vol. 74, Pg. 339, 1978.
human	TDLo	oral	80mg/kg/8D (80mg/kg)	VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION BLOOD: LEUKOPENIA	Lancet. Vol. 1, Pg. 444, 1978.
man	TDLo	intravenous	4286ug/kg/30M (4.286mg/kg)	LUNGS, THORAX, OR RESPIRATION: DYSPNEA SKIN AND APPENDAGES (SKIN): SWEATING: OTHER	Annals of Internal Medicine. Vol. 97, Pg. 374, 1982.
man	TDLo	oral	2857ug/kg (2.857mg/kg)	CARDIAC: OTHER CHANGES	Lancet. Vol. 1, Pg. 225, 1987.
man	TDLo	oral	51mg/kg/3D-I (51mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	American Journal of Medicine. Vol. 75, Pg. 875, 1983.
man	TDLo	oral	57mg/kg/5D-I (57mg/kg)	LIVER: "JAUNDICE, CHOLESTATIC"	Digestive Diseases and Sciences. Vol. 32, Pg. 333, 1987.
man	TDLo	oral	270mg/kg/3W-I (270mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: INTERSTITIAL NEPHRITIS	American Journal of Medicine. Vol. 70, Pg. 1272, 1981.
man	TDLo	unreported	600mg/kg/6W (600mg/kg)	SKIN AND APPENDAGES (SKIN): HAIR: OTHER	Lancet. Vol. 1, Pg. 1160, 1981.
mouse	LD50	intraperitoneal	306mg/kg (306mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 33, Pg. 1655, 1983.
mouse	LD50	intravenous	150mg/kg (150mg/kg)		Journal of International Medical Research. Vol. 3, Pg. 86, 1975.
mouse	LD50	oral	2550mg/kg (2550mg/kg)		Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 11, Pg. 1685, 1983.
mouse	LD50	subcutaneous	437mg/kg (437mg/kg)		Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 11, Pg. 1685, 1983.
rabbit	LD50	intraperitoneal	1063mg/kg (1063mg/kg)		Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 11, Pg. 1685, 1983.
rabbit	LD50	intravenous	164mg/kg (164mg/kg)		Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 11, Pg. 1685, 1983.
rabbit	LD50	oral	> 8640mg/kg (8640mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: CYANOSIS BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 11, Pg. 1685, 1983.
rat	LD50	intraperitoneal	328mg/kg (328mg/kg)		Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 11, Pg. 1685, 1983.
rat	LD50	intravenous	106mg/kg (106mg/kg)		Journal of International Medical Research. Vol. 3, Pg. 86, 1975.
rat	LD50	oral	5gm/kg (5000mg/kg)		Journal of International Medical Research. Vol. 3, Pg. 86, 1975.
rat	LD50	subcutaneous	860mg/kg (860mg/kg)		Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 11, Pg. 1685, 1983.
women	LDLo	intravenous	1008mg/kg/6W- (1008mg/kg)	VASCULAR: OTHER CHANGES	Drug Intelligence and Clinical Pharmacy. Vol. 17, Pg. 126, 1983.
women	TDLo	intravenous	4mg/kg/2M-C (4mg/kg)	CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP	Lancet. Vol. 1, Pg. 99, 1987.
women	TDLo	oral	30mg/kg/2D-I (30mg/kg)	BEHAVIORAL: ATAXIA BEHAVIORAL: REGIDITY BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)	Annals of Emergency Medicine. Vol. 16, Pg. 1162, 1987.

Consensus Reports：

 

SAFETY PROFILE：

Hazard Codes: T,Xn
Risk Statements: 60-42/43-36/37/38-20/22 
R60:May impair fertility. 
R42/43:May cause sensitization by inhalation and skin contact. 
R36/37/38:Irritating to eyes, respiratory system and skin. 
R20/22:Harmful by inhalation and if swallowed.
Safety Statements: 53-26-36/37/39-45-36-22 
S53:Avoid exposure - obtain special instructions before use.
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. 
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection. 
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) 
S36:Wear suitable protective clothing. 
S22:Do not breathe dust.
WGK Germany: 3
RTECS of Cimetidine (CAS NO.51481-61-9): MF0035500

Standards and Recommendations：

 

Analytical Methods：